l e t t e r s
Spatial heterogeneity of transcriptional and genetic markers between physically isolated biopsies of a single tumor poses major barriers to the identification of biomarkers and the development of targeted therapies that will be effective against the entire tumor. We analyzed the spatial heterogeneity of multiregional biopsies from 35 patients, using a combination of transcriptomic and genomic profiles. Medulloblastomas (MBs), but not high-grade gliomas (HGGs), demonstrated spatially homogeneous transcriptomes, which allowed for accurate subgrouping of tumors from a single biopsy. Conversely, somatic mutations that affect genes suitable for targeted therapeutics demonstrated high levels of spatial heterogeneity in MB, malignant glioma, and renal cell carcinoma (RCC). Actionable targets found in a single MB biopsy were seldom clonal across the entire tumor, which brings the efficacy of monotherapies against a single target into question. Clinical trials of targeted therapies for MB should first ensure the spatially ubiquitous nature of the target mutation.
Many cancer types show considerable intertumoral heterogeneity between individuals [1] [2] [3] . Molecular biomarkers are intended to (i) tailor treatment intensities 4, 5 , (ii) define oncogenic drivers for targeted therapies [5] [6] [7] , and (iii) identify diagnostic mutations (e.g., SMARCB1 mutations in atypical teratoid/rhabdoid tumors) 8 . Currently, clinical diagnoses are based on single biopsies, with the assumption of spatial homogeneity across tumors; however, spatial heterogeneity could lead to erroneous tumor classification or the selection of therapies against targets that are present only in a locally restricted portion of the tumor. These implications were recently highlighted in late-stage RCC 9, 10 , with highly divergent mutational profiles affecting MTOR and TP53, as well as demonstrating good and poor prognostic gene signatures in multiregion biopsies from the same tumor 10, 11 .
To determine the degree and clinical importance of spatial heterogeneity in MB, we performed multiregional biopsies and compared gene expression profiles, DNA copy-number alterations (CNAs), and somatic mutations. Our cohort included 9 primary MBs, 16 HGGs (10 with gene expression only 12 ), and 10 RCCs 10 , with 4-11 spatially distinct biopsies from each (median: 6). An overview of the data types available for each patient is presented in Supplementary Table 1a and Supplementary Figure 1 .
Glioblastoma 13 and MB 14 each comprise four distinct molecular subgroups that are discerned through analysis of transcriptional data. Unsupervised hierarchical clustering (HCL) of expression data has shown that MB biopsies form tight clusters apart from single samples [15] [16] [17] [18] [19] [20] (8/8 ; Fig. 1a, Supplementary Fig. 2a,b) , whereas in HGGs (3/3) and RCCs (8/9), multiregion biopsies from single individuals clustered apart when combined with single samples ( Supplementary  Fig. 2c-f) . Overall, on the basis of the s.d. of expression, intertumoral differences were greater than intratumoral heterogeneity in each tumor type (Fig. 1b) . Subtype prediction with Predictive Analysis of Microarrays (PAM) showed that 21% (13/63) of glioblastoma multiregion samples diverged from the most commonly observed subtype for each patient, compared with only 2% (1/52) of MB biopsies (P = 0.003; Fig. 1c-e, Supplementary Figs. 3-6 ). When we considered only Spatial heterogeneity in medulloblastoma biopsies with subgroup predictions of 100% confidence, we found that all MB tumors had concordant subgroup calls between multiple biopsies (9/9) , compared with only 55% of glioblastomas (6/11; P = 0.038; Fig. 1e ). We conclude that MB can be robustly and reliably subgrouped from only a single biopsy, but glioblastoma cannot.
We identified somatic CNAs by using a custom pipeline based on the TITAN algorithm 21 , which is robust to high levels of normal contamination (Online Methods). Regions of CNA were identified in all three tumor types (Fig. 2a, Supplementary Figs. 7 and 8, Supplementary  Table 1b,c) , and unsupervised HCL of clonal segments showed tight clustering of individual biopsies in the cohort across all tumor entities (Fig. 2b, Supplementary Fig. 9 ). CNA-derived measurements of spatial heterogeneity highlighted the variance between individuals for each tumor type (Fig. 2c) . Somatic single-nucleotide variants (SNVs) and insertions/deletions (indels) recapitulated a similar pattern of spatial heterogeneity across tumors (Fig. 2d, Supplementary  Table 1d ). Overall, on the basis of the mutation and CNA data, none of the three tumor types comprised only homogeneous or heterogeneous tumors; rather, each had a repertoire of tumors residing along a continuum of genetic heterogeneity. 
l e t t e r s l e t t e r s
This genomic complexity results from a process of clonal evolution whereby the successive acquisition of mutations and CNAs generates genetically related subpopulations of cells or lineages within each tumor. We integrated CNA and mutational data using the EXPANDS algorithm 22 , to infer the cellular lineage composition in each biopsy. EXPANDS detects multiple genetically distinct coexisting subpopulations of cells and allows phylogenetic reconstruction of their evolutionary relationships. Figure 3a , which describes the spatial distribution of genetically distinct subpopulations throughout a tumor, illustrates the clonal intermixing detected in many samples of the cohort (Fig. 3b-d, Supplementary Fig. 10 , Supplementary Table 1e,f). Many tumor biopsies had a major clone (i.e., a genotype present in >70% of tumor cells) that was also detected in a minority of cells in other biopsies from the same tumor (i.e., subclonal) or that was absent in other biopsies (for example, biopsies 3, 5, and 6 from tumor RCC7 were genetically similar to some cells in biopsy 4 (4a), but not all cells (4b clustered separately); Fig. 3c) . In some tumors, individual biopsies contained two or more cell lineages that independently accumulated distinct repertoires of mutations not found elsewhere in the tumor (e.g., HGG2 biopsies 1 and 5; Fig. 3c ). The presence of multiple genetically distinct cellular lineages within single biopsies has previously been linked to poor prognosis and treatment response across a variety of cancer types 23 .
This surprising but common pattern of major genetic clones in one biopsy that are subclonal or absent in spatially distinct locations in the same tumor prompted us to investigate observable mutation clonality HGG1  HGG2  HGG3  HGG4  MB2  MB3  MB5  MB6  MB7  RCC1  RCC2  RCC3  RCC4  RCC5  RCC6  RCC7  RCC8  RCC9  RCC10   HGG  MB  RCC   Entity   Patient   HGG1  HGG2  HGG3   HGG4  MB5  MB6   MB2  MB3  MB7   RCC1  RCC2  RCC3   RCC4  RCC5  RCC6   RCC7  RCC8 l e t t e r s l e t t e r s across biopsies, as clonality is a key requirement of clinically actionable therapeutic targets 24 . We classified mutations into clonal and subclonal populations ( Supplementary Fig. 11 , Supplementary Table 1g ) and determined whether the status of the subset of damaging clonal mutations changed between spatially separated tumor biopsies.
In nearly all tumors we found a predominance of clonal mutations that were subclonal or completely absent in additional biopsies ( Fig. 4a, Supplementary Fig. 12 ; validation set of seven mutations with a 96% validation rate across biopsies; Supplementary Fig. 13 , Supplementary Table 1h) . This observation held when we considered only driver events [25] [26] [27] [28] ( Fig. 4b , Supplementary Table 1i-k).
We predict that monotherapies against a single target identified in a single biopsy are unlikely to show dramatic clinical effects, as targets are not ubiquitous; this would leave untargeted clones in unsampled portions of the tumor free to survive and repopulate the tumor. When the goal of a cancer therapy is improved patient treatment, the clinically relevant question is whether the observed level of genomic spatial heterogeneity affects actionable or driver alterations. As proof of concept, we focused on a set of genes with known roles in cancer initiation and/or progression 29 , or with defined drug interactions 30 . These genes are enriched in relevant or actionable targets in a manner that is unbiased toward either of the cancer types we included (Supplementary Table 1l ,m). When we investigated the spectrum of SNVs, indels, and CNAs affecting these genes (Supplementary Figs. 14 and 15), we found a remarkable variety of patterns across tumors, including cases with only a small set of shared alterations across biopsies but with many events present in single biopsies (e.g., MET amplification in HGG4); homogeneous tumors with many shared actionable events (e.g., HGG3); cases without ubiquitous actionable targets, which may require multiagent targeted therapeutics (e.g., MB6); tumors that lacked vulnerability to any of the considered actionable targets in a subset of biopsies (e.g., MB7); and tumors with alterations that may predict resistance (e.g., TP53 compound loss and somatic mutation in RCC7).
Considering the full set of identified actionable mutations per tumor across all biopsies, we calculate that in each tumor entity, an average of at least five biopsies is required to provide an 80% chance of identifying at least 80% of these alterations. If these measures were reduced to 50%, sampling of at least two biopsies would be required, or as many as four for highly heterogeneous tumors (Fig. 5a) . This is probably an underestimation, as the detection of actionable mutations does not plateau in most patients (Supplementary Fig. 16 ). HGG2 HGG3 HGG4  MB2  MB3  MB5  MB6  MB7  RCC1  RCC10  RCC2  RCC3  RCC4  RCC5  RCC6  RCC7  RCC8  RCC9 Genetically distinct clonal lineages yield ON/OFF mutation patterns between spatially separated biopsies. (a) Nonsynonymous mutations binned into five categories: clonal in all biopsies (clonal); clonal in some biopsies and subclonal in others (clonal/subclonal); clonal in some biopsies and completely absent in others (clonal/absent); clonal in some biopsies, and subclonal or absent in others (clonal/subclonal/absent); and never detected as clonal (non-clonal). Top, illustration of the most favorable clinical scenario, in which most mutations are clonal across all biopsies (left), and the worst-case scenario, in which mutations are clonal in some biopsies but absent in others (right). Bottom, mutation patterns follow a worst-case scenario across tumor types. Tumor-specific polygons on radial plots indicate the proportion of mutations on each of the five axes, with polygon centers marked by black circles. (b) The proportion of driver mutations/indels (top) or CNAs (bottom) that are found in every biopsy of a given tumor (i.e., trunk events) when both clonal and subclonal or only clonal driver events are considered. The absolute numbers are shown above the bars.
l e t t e r s
Up-front profiling of numerous tumor regions to identify the full repertoire of actionable targets is neither practical nor likely, given the amount of sequencing required; thus we focused on maximizing the information derived from a minimal set of biopsies. Specifically, we wanted to determine how well we could predict the frequency of individual mutations across a tumor with an increasing number of biopsies, noting that prediction accuracy for mutations identified in a single fraction would be high only in very homogeneous tumors. We empirically determined the frequency of each alteration, considering all possible pairs of an increasing number of biopsies, and compared this observed quantity to the known frequency of the alteration in all biopsies; the difference between these values was the inference error of mutation frequency resulting from an insufficient number of biopsies from genetically heterogeneous tumors (Supplementary Fig. 17) . Using a 10% error rate as an acceptable threshold, we calculated for each tumor the number of observed mutation frequencies that fell within this range (i.e., accuracy). As expected, we found that accuracy improved with increasing numbers of biopsies, and also that brain tumors fall into two patterns. The first comprises more homogeneous tumors, which have fairly high prediction accuracy even with a low number of biopsies, and the second comprises more heterogeneous tumors for which multiple biopsies are required to ensure an accurate determination of mutation frequency (Fig. 5b) . In our cohort of MBs and glioblastomas, considering just two biopsies per tumor enabled the distinction of tumors with high versus low genetic heterogeneity, with high specificity especially for highly heterogeneous tumors (Fig. 5c, Supplementary Fig. 18 ).
Although spatial heterogeneity is clearly a barrier to highly effective therapeutics against an entire primary tumor, the extent of heterogeneity between primary and recurrent MB 31 is many fold greater (Fig. 6a, Supplementary Fig. 19 ). This vast discordance at relapse is therefore unlikely to be secondary solely to inadequate spatial sampling of the therapeutically naive primary tumor. In gliomas 32 , the recurrent disease resembles the primary tumor more closely, and only in rare cases diverges to the extent seen in MB, possibly as a result of less complete success in the resection of this more diffuse and infiltrating tumor. MB is known to recur from very rare populations of cells 31 ; thus, therapeutic approaches that can eradicate such cellular lineages despite their low prevalence in the primary tumor are severely needed.
Targeted cancer immunotherapy is based on the presence of tumor-specific cell-surface antigens, as opposed to cell-autonomous somatic mutations. We examined the expression of the antigens/genes for which chimeric antigen receptor T cells or monoclonal antibodies l e t t e r s already exist [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] , and we observed remarkable consistency of expression across multiregional biopsies, which contrasts sharply with the heterogeneity of somatic mutations across fractions in the same set of tumors. This was the case in all MBs examined, including those with high levels of genetic heterogeneity and for which targeted therapy would be problematic [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] (Fig. 6b, Supplementary  Fig. 20) . The homogeneity of the transcriptome versus the heterogeneity of somatic mutations in our MB cohort suggests that targeted immunotherapeutic approaches could potentially overcome the hurdle of spatial genetic heterogeneity. The vast majority of patients with brain tumors have their tumor classified from a single tumor biopsy, which is potentially adequate for MB, but not for glioblastoma. The extent of the spatial heterogeneity of somatic mutations observed in our cohort suggests that clinical trials of molecularly targeted therapy should first assess the ubiquitous distribution of the target. The lack of clonal actionable driver mutations that are ubiquitously present across all regions of a given brain tumor suggests that monotherapies that target a single gene from a single biopsy are unlikely to have dramatic effects in terms of improving the lives of patients with brain tumors.
URLs. Gene Expression Omnibus, https://www.ncbi.nlm.nih.gov/geo/; European Genome-phenome Archive, https://www.ebi.ac.uk/ega/.
MetHodS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
Genetic homogeneity Genetic heterogeneity l e t t e r s 12 ), and 10 renal cell carcinomas 10 ); peripheral blood samples were included as germline controls for all cases with exome sequencing. All multiregion biopsies for unpublished cases were obtained in situ during tumor resection, by mimicking the previous sample-preparation conditions of published cases to the best of our knowledge. Medulloblastoma tumors are similar in size to glioblastomas, with an average diameter of 8-12 cm; biopsies were taken from regions as far apart as possible by the surgeon. Owing to their localization in the abdomen, renal cancers may be larger in size. Detailed information on multiregion tumor samples is provided in Supplementary Table 1a and Supplementary Figure 1 . All patient material and clinical information was obtained after informed consent had been received and was approved by the institutional review boards of the contributing institutions. DNA and RNA extractions were performed as previously described 16 . RNA quality was assessed on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only high-quality RNA (RNA integrity number ≥ 7) was included for further study.
Gene expression profiling.
We carried out expression profiling on eight MB and three HGG multiregion biopsies, with a total of 72 biopsies and a median number of 6 multiregion biopsies per primary tumor (range: 4-9). We used Affymetrix HU133 Plus 2.0 microarrays for HGG samples, and Affymetrix Gene 1.1 ST arrays (Affymetrix, Santa Clara, CA) for MB samples, to ensure that these multiregion biopsies could be compared to published data sets [15] [16] [17] 20 .
Microarrays were processed according to the manufacturer's guidelines. Raw data were normalized with a transcript-level robust multi-array average (RMA) algorithm 44 , and subsequently clustered by unsupervised HCL (Pearson's dissimilarity -average linkage) in Partek Genomics Suite. The molecular classification of the multiregion biopsy samples was done with the class-prediction algorithm PAM 45 , as implemented in the pamr package (v. 1.51). Markers for glioblastoma (GBM) subtypes were obtained from the Verhaak classifier 13 . We note that classification was done for the GBM samples only, thus excluding HGG1. Subgroup-specific markers for MB were identified on the basis of oneway analysis of variance with multiple hypothesis correction by the Bonferroni method in previously published data sets with known subgroup affiliation 46 .
On the basis of the misclassification error values in core GBM 13 and MB [15] [16] [17] training data sets (Supplementary Fig. 6 ), we chose threshold values of 1.75 and 1 for multiregion samples from published 12 and unpublished GBM and MB patient data, respectively. The published GBM data set 12 was quantilenormalized with Partek Genomics Suite. Predicted subtypes or subgroups with confidence probabilities higher than established thresholds 46 were considered bona fide subgroup assignments. Samples with less than 500 ng of remaining RNA were analyzed with NanoString as previously described 46 . MB3 was analyzed exclusively with NanoString, as only limited amounts of RNA were available for all multiregion biopsies. NanoString counts were normalized to the three housekeeping genes (GAPDH, ACTB and LDHA). We prepared dot plots and principal component analyses based on normalized NanoString calls using the R statistical environment (v2.15.1). Pearson correlation was used to determine the correlation of marker gene expression for each biopsy per patient (intratumor comparison) and between each biopsy and all others samples from different patients of the same subgroups (intertumor comparison). The Wilcoxon rank-sum test was used to infer differences in intra-and intertumor marker gene expression in a subgroup-specific fashion. A previously published data set of nine multiregion RCC samples 9 profiled with the Affymetrix Human Gene 1.0 ST array was included in the analysis, as well as two RCC data sets 18, 19 with 53 and 29 single RCC samples, respectively. The RCC expression data sets were processed together in R (v3.1.1) with the oligo package (rma normalization), and the combat package was used for batch-effect correction. Unsupervised HCL (Pearson's dissimilarity -average linkage) was carried out with the Partek Genomics Suite.
Whole-exome sequencing. DNA libraries (MB1-5) from multiregion samples were exome-captured with Agilent SureSelect V5+UTR probes and subjected to eight cycles of PCR, and then paired-end 75-base reads were sequenced over two lanes on an Illumina HiSeq 2000 instrument per pool of six libraries. Reads were aligned to the human reference genome hg19a with Burrows-Wheeler Aligner (BWA) (version 0.5.7) 47 . Two lanes were merged with duplicates marked with Picard Tools (version 1.71). Additional samples (MB6-7 and HGG1-5) were subjected to paired-end library construction using Illumina's Nextera Rapid Capture Exome kit. Captured exome DNA sequences were then sequenced with Illumina HiSeq 2000 (rapid-run mode) for 100-bp paired-end reads. We used the FASTX toolkit to remove adaptor sequences and to trim low-quality reads. Quality trimmed reads were then aligned to the human reference genome (hg19) using BWA (version 0.5.9) 47 . We used Genome Analysis Toolkit (GATK) 48 for indel realignment. We marked duplicate reads with Picard so we could exclude them further in our analysis.
Somatic SNV detection and filtering. SNVs were called exome-wide with SAMtools mpileup (v0.1.7), and indels were called with VarScan. We carried out stringent filtering requiring no reads in the germline sample supporting an SNV to ensure conservative selection of somatic events. Variants with sufficient coverage (≥10) were further annotated with Annovar 49 (table_annovar.pl; RefSeq gene annotations, amino acid change annotation, SIFT, PolyPhen, LRT, and MutationTaster scores, PhyloP and GERP++ conservation scores, dbSNP identifiers, 1000 Genomes Project allele frequencies, NHLBI-ESP 6500 exome project allele frequencies).
Mutation validation.
We validated a subset of somatic mutations using PCR amplification from all tumor biopsies, matched germline, and a healthy control sample. We amplified regions of interest from genomic DNA with primers flanking each SNV (Supplementary Table 1h,n) , using Q5 HighFidelity DNA polymerase (NEB). PCR specificity was determined by agarose gel electrophoresis followed by gel extraction of specific bands using a Gel Extraction/PCR clean-up kit (Qiagen) according to the manufacturer's instructions. Purified amplicons were sequenced by Sanger sequencing, and traces were reviewed manually for the expected presence or absence of the mutated base.
Droplet digital PCR.
For the validation and quantification of the frequency of the PIK3CA SNV detected in MB3, we used droplet digital PCR (ddPCR), as Sanger traces were of poor quality in the region of interest. We used genomic DNA from six spatially distinct biopsies from MB3, as well as matched germline and a healthy donor control, in the assay. We validated the PIK3CA mutation (chr 3:178936091 G>A) by using the PrimePCR ddPCR mutation assay kit, PIK3CA p.E545K, human (Bio-Rad; dHsaCP2000075 (mutant, FAM) and dHsaCP2000076 (wild-type, VIC)), according to the manufacturer's instructions. Fluorescence measurement with a QX100 ddPCR droplet reader (Bio-Rad) was used to detect the presence of mutant and wild-type alleles. QuantaSoft Analysis software (Bio-Rad) was used in the quantification.
Copy-number analysis. TITAN 21 estimates the cellular prevalence of tumor cell populations (lineages) on the basis of a user-defined number of clonal clusters, and user-defined ploidy estimation. Thus, we carried out 20 runs of TITAN for each exome, with cluster numbers 1-10 (representing one clonal lineage through to ten coexisting clonal lineages with distinct genotypes), and ploidy set to either 2 or 4. Copy-number segments from the 20 parameter combinations were analyzed and merged into larger segments if they were on the same chromosome arm, were <10 Mb apart, and had the same state (loss or gain). We compared merged results from each of the 20 parameter combinations for each biopsy in order to select the optimal parameter combination as the highest-scoring, considering the following criteria:
# maximize the largest contig size # maximize the median contig size # minimize the number of contigs # minimize the number of clonal clusters
The parameter combination with the largest x value was selected as optimal:
where L is the largest contig size (Gb), M is the median contig size (Gb), T is the total number of contigs, and C is the number of clonal clusters.
We next assessed the prevalence of copy-number segments (loss or gain) identified in the best parameter combination of a unique biopsy (i.e., target segments), using either all segments or clonal segments only (logratio ≥ |0.2|). A target segment was considered as found in another biopsy from the same tumor if any of the 20 parameter combinations contained a segment with the same state (loss or gain), and whose span had a minimum reciprocal overlap of at least 70% with the target segment.
Concordance of driver regions of loss and gain in the RCC tumor cohort was performed for our calls and the published data 9 . With our computational approach, we achieved 97% concordance compared with the manual curation performed previously 9 , indicating that this method is specific and sensitive despite the high level of normal cell contamination in these tumors. Conversely, compared to our results for the subset of copy-number gains and losses identified in ref. 9 , the manual curation showed 89% concordance to the TITAN pipeline, indicating that our approach is more sensitive, and that the homogeneity of certain copy-number driver events may be greater than previously estimated (Supplementary Table 1c) . Finally, our approach is applicable genome-wide and across tumor types in a highly parallel fashion.
SNV classification using mclust. We classified variant allele frequencies (VAFs) of somatic SNVs into distinct clusters using the R package mclust 50 , which uses finite mixture estimation via iterative expectation maximization steps and the Bayesian information criterion. Each cluster is manually categorized as 'homozygous' , 'clonal' , or 'subclonal' , depending on the cluster VAF and the uncertainty separating it from the next cluster, and taking into account the biopsy tumor cell content value reported by TITAN. Multiple subclonal populations are numbered sequentially, starting with the most highly prevalent population. Clonal and subclonal mutation details per biopsy are summarized in Supplementary Table 1d,g.
Phylogenetic reconstruction from combined SNV and CNA data. We combined copy number and loss-of-heterozygosity (LOH) information derived from TITAN (including the clonal and subclonal events identified in the best parameter combination run for each biopsy), as well as somatic mutations and SNPs in areas of LOH, to infer tumor phylogenies using EXPANDS 22 . We ran EXPANDS v1.7.2 with the runExPANdS function. All parameters were set to default, with the exception of maxScore, which was lowered to 1.5 to reduce the false positive rate of subpopulation detection. Only subpopulations with a minimum size (cellular frequency) of 0.1 were considered. Mutations that could not be assigned to a high-confidence subpopulation were discarded, so that no ambiguous assignments were made. In addition, ambiguous subpopulations (i.e., groups of mutations and copy-number events) were dropped from the analysis. Mutations were assigned to all nested subpopulations (i.e., if a mutation was found in a subpopulation of cells at a high frequency of 0.8, it was also assigned to 'daughter' subpopulations of, for instance, frequency 0.5), to report the assignment of every mutation to all detected subpopulations in all biopsies of the tumor (assuming that the mutation could be assigned unambiguously as mentioned above; Supplementary Table 1f) .
Phylogenetic relationships between the subpopulations inferred by the EXPANDS algorithm in all biopsies per patient were generated using both SNV and copy-number segments. The Manhattan distance metric was used to calculate pairwise distances between all pairs of biopsies on the basis of these data, and a complete linkage HCL was performed to generate phylogenies. Germline-rooted trees were generated with the as.phylo R function from the ape package.
Error inference of actionable genetic alterations.
In order to analyze genetic heterogeneity affecting actionable and putative driver genes in a way that was unbiased toward any of the tumor types, we opted to use general lists of known cancer drivers and druggable targets. Sets of genes known to be drivers in GBM, MB, and RCC tumors come from studies of different cohort sizes, with sometimes unknown subgroup affiliations, and thus are not equally comprehensive. To overcome this, we used a list of genes of interest that included putative driver genes found in the Cancer Gene Census database 29 (n = 572) and actionable genes from the Drug-Gene Interaction Database 30 (n = 426 genes) (Supplementary Table 1l,m) .
Oncoprint plots (R package ComplexHeatmap v1.6.0) were built for the combination list of these genes for all tumors, using (a) clonal mutations and indels and (b) clonal mutations and indels plus high-level CNAs (>4 copies gained; homozygous loss). A manual review of the results showed that the absence of clonal somatic mutations in subsets of biopsies is not explained by concordant copy-number loss. Because not all biopsies had copy-number data, we carried out further analyses using results from strategy (a) in order to maximize the number of usable biopsies per tumor.
Driver event lists. The MB CNA driver events listed in Supplementary  Table 1i ,j and Figure 4b were taken mainly from Shih et al. 27 , with a subset of the mostly highly recurrent genes listed in Northcott et al. 25 . The HGG chromosome arm and recurrent driver gene events were retrieved from Tables 1  and 2 Table S4 (q-value threshold: 0.05) of the ccRCC TCGA paper 28 . The cancer cell fraction values presented in Supplementary Figure 10b for driver mutations were calculated as previously described 51 :
CCF VAF*(1/Purity)(CN*Purity +2(1 Purity)) = −
where CCF is the cancer cell fraction, VAF is the variant allele frequency, CN is the copy number at the mutation, and Purity is the tumor purity as calculated by EXPANDS.
Accuracy of mutation-frequency detection. We calculated the inferred error of the prevalence of each mutation across biopsies by using a subsampling approach. In each tumor, given a subset of biopsies from 1 to n (where n is the total number of biopsies per tumor), we calculated the frequency of each identified mutation in the biopsies sampled as f o . We subtracted this value from the 'ground truth' expected frequency for that mutation across all n biopsies (f e ). When the observed and expected values were identical, then the inferred error (f e -f o ) was 0. In the majority of tumors, there is a predominance of genes with mutations in single biopsies, leading to negative values of error for many genes, as the frequency of the mutation is often overestimated (Supplementary Fig. 17) . In contrast, genes that are present in all but one or two biopsies will often have an error value greater than 0, as their frequency can be underestimated. The likelihood of being within ±0.1 of 0 (i.e., close to perfect accuracy, given the data from all biopsies) is calculated as the proportion of genes at each sampling of 1:n biopsies where the error rate was within those bounds. For instance, we sampled all possible combinations of a certain number of biopsies from the total number of biopsies, and in each case calculated the inferred error of each detected mutation's prevalence. The proportion of the total set of error values < |0.1| represented the likelihood of a correct interpretation of mutation frequency given that number of biopsies (Fig. 5b) .
Estimation of genetic heterogeneity from two biopsies. To address the practical issue of estimating genetic heterogeneity from a minimum number of informative biopsies, we implemented a simple metric of the proportion of mutated genes in a set of two biopsies that was ubiquitous (i.e., present in two of two biopsies). The mean value of all pairs of biopsies from a total of n biopsies per tumor showed a strong divergence in HGG and MB tumors, with high-versus low-variability tumors well separated (Fig. 5c) . These were the same tumors that scored as high versus low variability on the basis of the accuracy metric described above.
We also observed clear separation of these two classes with the R package mclust (Supplementary Fig. 18a ), which models univariate mixtures of Gaussian distributions (i.e., corresponding to a mixture of high-and lowgenetic-variance brain tumors) via expectation maximization and the Bayesian information criterion 50 . Using two thresholds from the mclust density peaks (low, 0.55; high, 0.75), we calculated the accuracy of the classification of highvariance versus low-variance tumors on the basis of a single pair of biopsies, and observed that high-variance tumors in particular had high true positive and low false positive classification rates (Supplementary Fig. 18b ). On the basis of this metric, the vast majority of pairs of biopsies from tumors with high genetic heterogeneity have a low percentage of gene mutations found in both biopsies, such that they are always classified as heterogeneous tumors, and almost never as homogeneous tumors.
Expression analysis of immunotherapeutic targets in MB tumors.
Microarray expression data from the Affymetrix Gene 1.1 ST array (Affymetrix, Santa Clara, CA) for the MB samples were analyzed in the R environment (v3.1.1). We used the affy package (v1.44.0) and the custom CDF hugene11sth-sensgcdf (v19.0.0) to summarize the expression of 21,641 Ensembl (ENSG) genes and process the data. Expression data were normalized via the rma method.
Spatial genetic variance versus post-treatment clonal evolution. To directly measure the relative contributions of spatial heterogeneity and clonal evolution induced by treatment, we used our previously published cohort of matched pre-and post-therapeutic MB samples 31 . This comparison showed that in MB, the amount of divergence observed between primary and relapse compartments far exceeded the spatial genetic variance in the primary tumor.
To assess whether the observed divergence between primary and recurrent MB is greater than the observed divergence between intratumoral biopsies, we reanalyzed the 14 primary-relapse tumor whole-genome sequencing (WGS) samples with matched germline, using the same pipeline as presented above. Briefly, mutations were called using SAMtools mpileup, filtered stringently against the germline, and shortlisted to those mutations with at least tenreads coverage in both primary and recurrent samples, and are in areas of normal copy number and LOH. Because the samples in this work were exomes, we restricted the analysis of the primary-relapse samples to the same exonic regions. After removing the major analysis pipeline differences, we addressed differences in depth of coverage. The exome libraries were sequenced to an average of 60×, and the WGS samples were sequenced to 30× coverage. Thus, our ability to assess the similarity between regions in the exome libraries was more sensitive to subclonal events present at low levels (and therefore preferentially detectable by exome sequencing, and not by WGS). We addressed this bias by restricting the analysis to clonal events in the exomes, as clonal mutations are detectable in both exomes and genomes. To verify that this was a reasonable assumption, we compared the VAF of mutations found in the exomes to those found in matched WGS data generated from the same samples, but sequenced at 30× coverage. Matched WGS samples were available for biopsy 1 in each MB tumor with multiregional profiling. In all cases, we found that >75% of mutations with a VAF < 0.18 in the MB exomes were not found in the matched genomes sequenced from the same samples, which indicates that subclonal events are typically not well profiled at the shallower depths of a genomic library. Therefore, we restricted our analysis to clonal events in both exomes and genomes.
Focusing on the clonal and homozygous events detectable in both exome and genome data, we hypothesized that any differences between primary and relapse samples that were greater than the differences expected from different biopsies in a primary tumor would be largely attributable to clonal evolution as a consequence of therapy. To see whether the data supported this conclusion, we used the mutations in each biopsy to measure the pairwise concordance between all biopsies of individual tumors. Concordance was measured as the number of mutations in common between two biopsies, as a fraction of the total number of mutations present in both. In parallel, we used the mutations in the primary and relapse samples to measure pairwise concordance values between disease compartments. As a positive control, we compared the interbiopsy and intercompartmental concordance values of an adult GBM sample with multiple biopsies profiled before and after therapy (patient 17 from ref. 32 ).
In MB samples we found a mean pairwise concordance of 0.3903 between biopsies of the same tumor-nearly an order of magnitude higher than the mean concordance (0.03852) observed between disease compartments (Wilcoxon rank-sum test P value < 2.2 × 10 −16 ). One sample stood out as an outlier (MB-REC-04), and we note that in that case the tumor was a group 4 local recurrence. This unusual pattern of recurrence for a group 4 tumor may indicate that the primary mass was sub-totally resected rather than grossly resected, thus explaining the higher similarity of the recurrent compartment to the primary.
In the case of the adult GBM patient (patient 17) with multiregionally sampled primary (three regions; low-grade glioma) and recurrent disease (four regions; high-grade glioma), we found the same trend: the primary-relapse mean concordance of 0.01506 was an order of magnitude smaller than the mean intrabiopsy concordance of 0.5036 (Wilcoxon rank-sum test P value = 0.0001406). There was no significant difference between the primary-relapse MB concordance and the primary-relapse GBM concordance observed in patient 17 (Wilcoxon rank-sum test P value = 0.5458). Similarly, there was no significant difference between the regional biopsies in GBM versus MB (Wilcoxon rank-sum test P value = 0.09926).
Finally, the primary-relapse divergence calculated from reprocessed data from patient 17 was on par with that initially presented in the glioma paper 41 ; thus we included, for visual comparison, all the primary-relapse values for the glioma cohort in Figure 6a Statistical analysis. All statistical analyses were performed in the R statistical environment. Comparisons of categorical variables between entity types were done by two-sided Fisher's exact test. Comparisons of distributions were done by Welch two-sample t-test (parametric) or Wilcoxon rank-sum test (nonparametric). P values < 0.05 were considered statistically significant. Data availability. The Gene Expression Omnibus accession codes for the previously unpublished gene expression data are GSE62802 (HGG samples) and GSE62803 (MB samples). The Toronto whole-exome sequencing data sets have been deposited in the European Genome-phenome Archive under accession codes EGAD00001000723 and EGAS00001001014.
